Niraparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Niraparib (ncit:C80059)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BARD1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
Sensitivity (+) BRIP1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
Sensitivity (+) BRIP1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
Sensitivity (+) CDK12 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
Sensitivity (+) BRCA1 pathogenic variants Ovarian Epithelial Tumor Niraparib
Sensitivity (+) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
Sensitivity (+) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
Sensitivity (+) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
Sensitivity (+) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Niraparib
Sensitivity (+) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone